[go: up one dir, main page]

WO2006134482A8 - Procédé pour la fabrication d’atorvastatine, de ses sels pharmaceutiquement acceptables et de ses intermédiaires - Google Patents

Procédé pour la fabrication d’atorvastatine, de ses sels pharmaceutiquement acceptables et de ses intermédiaires

Info

Publication number
WO2006134482A8
WO2006134482A8 PCT/IB2006/001613 IB2006001613W WO2006134482A8 WO 2006134482 A8 WO2006134482 A8 WO 2006134482A8 IB 2006001613 W IB2006001613 W IB 2006001613W WO 2006134482 A8 WO2006134482 A8 WO 2006134482A8
Authority
WO
WIPO (PCT)
Prior art keywords
intermediates
pharmaceutically acceptable
acceptable salts
producing
producing atorvastatin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2006/001613
Other languages
English (en)
Other versions
WO2006134482A1 (fr
Inventor
Shanghui Hu
Junhua Tao
Zhiyi Xie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp Belgium
Pfizer Corp SRL
Original Assignee
Pfizer Corp Belgium
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Corp SRL filed Critical Pfizer Corp Belgium
Priority to EP06765533A priority Critical patent/EP1893767A1/fr
Priority to CA002612293A priority patent/CA2612293A1/fr
Publication of WO2006134482A1 publication Critical patent/WO2006134482A1/fr
Anticipated expiration legal-status Critical
Publication of WO2006134482A8 publication Critical patent/WO2006134482A8/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/10—Nitrogen as only ring hetero atom

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention décrit un nouveau procédé de fabrication de l’atorvastatine, de ses sels pharmaceutiquement acceptables et de ses intermédiaires en utilisant une aldolase. Des composés ainsi préparés sont utiles comme inhibiteurs de l’HMG-CoA réductase et peuvent ainsi être utilisés comme agents hypolipémiant et hypocholestérolémique.
PCT/IB2006/001613 2005-06-16 2006-06-06 Procédé pour la fabrication d’atorvastatine, de ses sels pharmaceutiquement acceptables et de ses intermédiaires Ceased WO2006134482A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP06765533A EP1893767A1 (fr) 2005-06-16 2006-06-06 Procédé pour la fabrication d atorvastatine, de ses sels pharmaceutiquement acceptables et de ses intermédiaires
CA002612293A CA2612293A1 (fr) 2005-06-16 2006-06-06 Procede pour la fabrication d'atorvastatine, de ses sels pharmaceutiquement acceptables et de ses intermediaires

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69106505P 2005-06-16 2005-06-16
US60/691,065 2005-06-16

Publications (2)

Publication Number Publication Date
WO2006134482A1 WO2006134482A1 (fr) 2006-12-21
WO2006134482A8 true WO2006134482A8 (fr) 2008-03-06

Family

ID=36928182

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/001613 Ceased WO2006134482A1 (fr) 2005-06-16 2006-06-06 Procédé pour la fabrication d’atorvastatine, de ses sels pharmaceutiquement acceptables et de ses intermédiaires

Country Status (6)

Country Link
EP (1) EP1893767A1 (fr)
JP (1) JP2006345863A (fr)
AR (1) AR055975A1 (fr)
CA (1) CA2612293A1 (fr)
TW (1) TW200724688A (fr)
WO (1) WO2006134482A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2017267A1 (fr) * 2007-07-16 2009-01-21 LEK Pharmaceuticals D.D. Synthèse de statine
US8183397B2 (en) 2007-04-03 2012-05-22 Lek Pharmaceuticals D.D. Synthesis of statins
WO2009019561A2 (fr) 2007-08-03 2009-02-12 Pfizer Products Inc. Procédé de préparation de composés chiraux
US8404870B2 (en) 2008-01-23 2013-03-26 Lek Pharmaceuticals D.D. ((2S,4R)-4,6-dihydroxytetrahydro-2H-pyran-2-yl)methyl carboxylate and process for the production thereof
EP2655650B1 (fr) 2010-12-20 2017-12-20 LEK Pharmaceuticals d.d. Synthèse enzymatique d'un principe actif pharmaceutique et de ses intermédiaires
EP2465936A1 (fr) 2010-12-20 2012-06-20 LEK Pharmaceuticals d.d. Synthèse enzymatique de statines et intermédiaires associés
JP5705580B2 (ja) * 2011-02-21 2015-04-22 公益財団法人微生物化学研究会 チオアミド化合物、チオアミド化合物の製造方法、［（４ｒ，６ｒ）−６−アミノエチル−１，３−ジオキサン−４−イル］アセテート誘導体の製造方法、及びアトルバスタチンの製造方法
CN103060396B (zh) * 2011-10-21 2017-09-12 武汉启瑞药业有限公司 一种生产高手性纯度的阿托伐他汀钙的新方法
WO2013068917A1 (fr) * 2011-11-07 2013-05-16 Dr. Reddy's Laboratories Limited Procédés de production d'un intermédiaire de statine lactone par oxydation enzymatique
CN105272954B (zh) * 2014-06-27 2017-10-13 上海弈柯莱生物医药科技有限公司 一种6‑取代甲基‑4‑羟基四氢吡喃‑2‑酮及其衍生物的制备方法
CA3025584A1 (fr) 2016-06-30 2018-01-04 Ardra Bio Inc. Procedes et microorganismes pour produire des aromes et des substances chimiques de fragrances

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7414119B2 (en) * 2002-09-20 2008-08-19 Verenium Corporation Aldolases, nucleic acids encoding them and methods for making and using them

Also Published As

Publication number Publication date
EP1893767A1 (fr) 2008-03-05
CA2612293A1 (fr) 2006-12-21
WO2006134482A1 (fr) 2006-12-21
TW200724688A (en) 2007-07-01
JP2006345863A (ja) 2006-12-28
AR055975A1 (es) 2007-09-12

Similar Documents

Publication Publication Date Title
WO2005014539A3 (fr) Inhibiteurs nouveaux de l'hmg-coa reductase a base de pyrrole
DK1341785T3 (da) Hydrolyse af R (R*,R*)-2-(4-fluorphenyl)-beta.delta-dihydroxy-5 (1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrol-1-heptansyrester med calciumhydroxid
EP2517706A3 (fr) Procédés et composés pour la production d'inhibiteurs de la dipeptidyl-peptidase IV et leurs intermédiaires
DE60239428D1 (fr)
BR0116785A (pt) Processo para a sìntese da forma v de atorvastatina e fenilboronatos como compostos intermediários
WO2012002741A3 (fr) Procédé de préparation d'inhibiteurs de la hmg-coa réductase et leurs intermédiaires
HUP0402590A3 (en) Method of manufacturing an amorphous form of the hemi-calcium salt of (3r,5r)7-3-phenyl-4-phenylcarbomoyl-2-(4-fluorophenyl)-5-isopropyl-pyrrol-1-yl!-3, 5-dihydroxyheptanoic acid (atorvastatin)
CA2560252A1 (fr) Procede de production d'atorvastatine calcique sous forme amorphe
WO2006134482A8 (fr) Procédé pour la fabrication d’atorvastatine, de ses sels pharmaceutiquement acceptables et de ses intermédiaires
WO2006067456A3 (fr) Processus chimiques
IL163279A (en) Process for the manufacture of hmg-coa reductase inhibitory mevalonic acid derivatives
WO2007057225A3 (fr) Procede de preparation de montelukast et produits intermediaires utilises pour la preparation
BRPI0417138A (pt) n-alquil-pirroles como inibidores de hmg-coa-redutase
WO2007039125A3 (fr) Composes
WO2007096903A3 (fr) Nouvelle forme cristalline d'hemi-calcium d'atorvastatine
WO2005105079A3 (fr) Nouveaux imidazoles
WO2009007856A3 (fr) Nouveau polymorphe d'atorvastatine calcium et son utilisation pour la préparation d'atorvastatine calcium amorphe
BRPI0506865A (pt) inibidores de hmg-coa redutase inusitados, baseados em imidazóis
WO2006122644A3 (fr) Procede de production de statines
AU2002356423A1 (en) Process for the preparation of amorphous atorvastatin calcium
WO2005030183A3 (fr) Nouveau procede de preparation de comprimes de calcium d'atorvastatine
WO2009054693A3 (fr) Procédé de préparation d'atorvastatine
WO2007057703A3 (fr) Procede et intermediaires pour la preparation de statines
WO2006059210A3 (fr) Pyrrols bicycliques fusionnes comme inhibiteurs de la reductase as hmg-coa
AU2002337600A1 (en) Fed batch solid state fermentation for the production of hmg-coa reductase inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006765533

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2612293

Country of ref document: CA

NENP Non-entry into the national phase in:

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWP Wipo information: published in national office

Ref document number: 2006765533

Country of ref document: EP